Human Immunodeficiency Virus (HIV)-infected patients are at increased risk for cardiovascular diseases partly due to chronic inflammation. Some antiretroviral drugs and Highly Active Anti-Retroviral Therapy (HAART) regimens seem to be related and amplify this increased risk, especially the ones containing abacavir. Platelet-Activating-Factor (PAF) is a potent inflammatory mediator that is implicated in both cardiovascular diseases and HIV-related manifestations. Our objective is to study the in vivo effect of the abacavir/lamivudine/efavirenz first-line HAART regimen on PAF metabolism in HIV-infected patients. The specific activities of PAF basic biosynthetic enzymes in leukocytes and platelets, PAF-cholinephosphotransferase (pAF-CPT) and lyso-PAF-acetyltransferase (Lyso-PAF-AT), but also those of PAF-basic catabolic enzymes, PAF acetylhydrolase (PAF-AH) in leukocytes and platelets and Lipoprotein-associated-Phospholipase-A 2 (LpPLA 2 ) in plasma, were measured in blood samples of 10 asymptomatic naive male HIV-infected patients just before and after 1,3 and 6 months of treatment. CD4 cell counts, viral load and several biochemical markers were also measured in the same blood samples of these patients. The repeated ANOVA measures and the Pearson r criterion were used for studying statistical differences and correlations -partial correlations respectively. Even though viral load was decreased and CD4 cell counts were beneficially increased after treatment with the abacavir/ lamivudine/efavirenz regimen, the main enzyme of the remodelling PAF-synthesis that is implicated in pro-atherogenic inflammatory procedures, Lyso-PAF-AT activity, was increased at 3 months oftreatment in both leukocytes and platelets, while the main enzyme of PAF-degradation, PAF-AH, was increased as a response only in leukocytes at the 3 rd month. Although the abacavir/lamivudine/efavirenz HAART regimen exhibits very efficient antiretroviral activities, on the other hand it induces an in vivo transient
increase in the inflammation-related remodeling PAF-biosynthetic pathway. This finding supports the hypothesis of inflammation-mediated increased cardiovascular risk in HIV-infected patients during the first months of abacavir-containing HAART.
Platelet Activating Factor (PAP) is an ubiquitous alkylphospholipid (1) that participates in several patho-physiological situations (2) . PAF acts through a specific receptor belonging to the family of seven spanning membrane domain receptors (PAF-R), that is found in a variety of cell types, including key cells ofthe innate immune and haemostatic systems: neutrophils, monocytes, leukocytes and platelets (2, 3) . Unregulated PAF-synthesis or defects in the mechanisms that limit its biological activities could cause chronic inflammation and thrombosis which are implicated in various pathological situations, including cardiovascular disease (1-5).
PAF biosynthesis can be accomplished through two different enzymatic routes, namely the de novo and the remodeling pathways (6) . Although several enzymes participate in the PAF biosynthesis, the dithiothreitol-insensitive CDP-choline: 1-0-alkyl-2acetyl-sn-glycerol cholinephosphotransferase (PAF-CPT, EC 2.7.8. 16 ) and the lyso-PAF:acetyl-CoA acetyltransferase (Lyso-PAF-AT, EC 2.3.1.67) are considered as the key-enzymes of the de novo and the remodelling pathway, respectively (6) .
The de novo pathway seems to be responsible for the constitutive production of PAP, maintaining its physiological levels in various tissues and blood. However, its basic enzyme, PAF-CPT, seems to be implicated in systemic inflammatory manifestations such as cancer (7) , central nervous system failure (8) and AIDS (9) . On the other hand, although it is well established that the remodeling pathway is activated mainly during acute inflammatory disorders, it has also been found to be activated in systemic ones (7, 9, 10) . Its main enzyme lyso-PAF-AT under resting conditions contributes to membrane glycerophospholipids production and membrane biogenesis, while upon acute inflammatory stimulation leads to PAF production (10) .
The main enzyme involved in the catabolism of PAP is PAF-acetylhydrolase (PAF-AH, EC 3.1.1.47), also known in plasma as lipoprotein-associated phospholipase A 2 (Lp-PLA), which cleaves the short acyl chain at the sn-2 position and forms lyso-PAF, a biologically inactive molecule (11) . PAF has broad effects on innate immunity and it is a well known participant in HIV infection and its manifestations such as AIDS dementia, Kaposi's sarcoma and HIV-associated nephropathy (12) (13) (14) . Monocytes are one of the major targets of HIV infection and play an important role in the pathogenesis of AIDS. They are able to serve as a reservoir of virus and viral products, and they may carry the virus into the tissues (15) . It has been reported that HIV-l-infected monocytes overexpress PAF (16) and that Tat-induced PAF synthesis plays a critical role in triggering the events involved in inflammatory activation of endothelial cells and a migratory response of monocytes (14) , resulting in increased permeability of the endothelium (12-16), a crucial event in the initiation of atherosclerotic complications (5) .
Moreover, PAF is also reported to contribute in amplification of viral growth in HIV-l-infected macrophages upon uptake of apoptotic cells (17) . With this point ofview, we have previously described that PAP biosynthesis is induced in patients with early HIV infection compared to control subjects, an induction that was more profound in HIV-infected patients with higher viral load levels just before HAART initiation (9) .
Since HIV-infected patients are at increased risk for cardiovascular disease partly due to chronic inflammation (18) (19) (20) , it is possible that increased PAF-levels during HIV infection contribute to this risk. Some antiretroviral drugs are also associated with increased cardiovascular risk (18) (19) . On the other hand, several studies have shown that virological suppression with antiretroviral therapy actually improves some of the surrogate markers of CVD (19) . In addition, interrupting antiretroviral therapy may increase coronary risk (19) .
Wehave previously described that apart from their general antiretroviral activity, several antiretroviral drugs and HAART combinations, such as tenofovir-DF, exhibited an inhibitory effect against PAF biological activities (20) . Moreover, in HIV patients treated with tenofovir-DF/emtricitabine/efavirenz for a 6-month period, a reduction of PAP biosynthesis and catabolism in leukocytes was observed together with a reduction in viral load and an increase in CD4 cell counts (21) .
On the other hand, abacavir as well as other antiretrovirals, exhibited no or weak anti-PAF action (20) . In addition, abacavir or HAART regimens containing abacavir have been associated with increased cardiovascular risk, especially in the first months of treatment (22) . The magnitude and mechanisms of risk reported to be associated with recent use of abacavir remain undefined (18) , but seem to be related with an increase of the host inflammatory status, at least for the first 6 months of treatment (18, 22) .
In order to examine any possible implication of increased PAF levels in the mechanism of abacavirrelated cardiovascular risk, we examined the in vivo effects of an abacavir-containing first-line HAART regimen on PAP-metabolism. For this purpose, we measured the specific activities ofPAF key metabolic enzymes, PAF-CPT, Lyso-PAF-AT and PAF-AH of human leukocytes and platelets, as well as LpPLA z in plasma of 10 narve, male HIV-infected patients before and after 1, 3 and 6 months of treatment with the abacavir/lamivudine/efavirenz HAART regimen. We also studied any potential correlation between these enzymes and other biochemical parameters such as viral load, CD4+ cell counts, lipid profile and hepatic enzymes.
MATERIALS AND METHODS
Centrifugations were performed in an Heraeus Labofug 3L-R, an Heraeus Labofug 400R (Heraeus Hanau, Germany) and a Sorvall RC-5B refrigerated super speed centrifuge (DuPont de Nemours & Co., Inc., Sorvall Instruments Div., Newtown, CT, USA) and a refrigerated Micro 22R Zentrifugen Hettich super speed centrifuge (Hettich, Kirchlengern, East Westphalia, Germany). Homogenizations were conducted at 30% of power of a supersonic Bandelin Sonoplus HD 2070 sonicator (BHD, Berlin, Germany). The liquid scintillation counter used was a 1209 Rackbeta (Pharmacia, Wallac, Finland). Platelet aggregation studies were performed in a model 400 VS aggregometer of Chrono-Log (Chrono-Log, Havertown, PA, USA) coupled to a Chrono-Log recorder at 37°C with constant stirring at 1200 rpm.
Bovine Serum Albumin (BSA), PAF (l-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine), trichloroacetic acid (TCA), CDP-choline, lyso-PAF, acetyl-CoA, dithiothreitol (DTT), EDTA, MgCl z ' Tris and analytical reagents and solvents were purchased from Sigma (Sigma, St. Louis, MO, USA). 1-0-hexadecyl-2-[3H]acetyl-snglycerol-3-phosphocholine (PH]-PAF) with a specific activity of 10 Ci/mmol was obtained from New England Nuclear (NEN, Dupont, Boston, MA, USA). 1-0-alkyl-2sn-acetyl-glycerol (AAG) was purchased from BIOMOL International LP (BIOMOL-ILP, Palatine House, Matford Court, Exeter, UK). 2,5-Diphenyloxazole (PPO) and 1,4-bis(5-phenyl-2-oxazolyl) benzene (POPOP) were purchased from BDH Chemicals (BDH, Dorset, England). Scintillation liquid cocktail (dioxane base) was prepared by diluting 7.0 g PPO, 0.3 g POPOP and 100 g Napthalene in 200 mL Hp and then transferred to I L of dioxane. Liquid chromatography grade solvents and silica G for TLC were purchased from Merck KGaA (Merck, Darmstadt, Germany).
CD4 cell counts were automatically calculated using Tetra One System on the Beckman Coulter EPICS XL flow cytometer (Beckman Coulter, Nyon, Switzerland), while viral load was determined using the Versant HIV-1 RNA 3.0 assay (bDNA). The kit for this assay was purchased by Siemens Healthcare Diagnostics, (Siemens, Tarytown, NY, USA.) Serum total cholesterol (TC), HDL-Cholesterol, LDL-Cholesterol, triglycerides, oxaloacetic transaminase (AST), pyruvic transaminase (ALT), alkaline phosphatase (ALP), y-Glutamyltransferase (y-GT), creatinine and all the other biochemical parameters were measured in a Siemens Dimension RxL automatic analyzer (Siemens Center, 60 MacPherson Road, Singapore).
Study design
Study enrollment began after obtaining approval from the local ethics committee. All patients signed the informed consent of participation in the study. They were randomly recruited from the 3rd Internal Medicine Department-Infectious Diseases Unit, Red Cross General Hospital, Athens, Greece. All subjects were male (n = 10) and they had evidence, of HIV infection as determined by the presence of antibodies against HIV measured by enzyme-linked immunosorbent assay (ELISA) and confirmed by Western blot. AIDS was identified on the basis of the revised criteria of the Centers for Disease Control. These patients were asymptomatic and fulfilled the criteria for HAART initiation, based on their levels in both CD4 cell counts and viral load. These criteria were applied according to European (European AIDS Clinical Society Guidelines, version 5, 2009) and international guidelines (Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of Antiretroviral Agents in HIV-I-Infected Adults and Adolescents, Department of Health and Human Services. December 1, 2009;1-161. Available at http://www.aidsinfo.nih.gov/ ContentFiles/ AdultandAdolescentGL.pdf).
Subjects with symptoms or signs of acute infection or other inflammatory manifestations such as periodontal or renal diseases were excluded from the study. None of the subjects had diabetes, renal failure, nephritic syndrome, active hepatitis or cirrhosis, or took medication for treatment of hyperlipidemia at the time of the study.
Patients received the HAART regimen abacavir/ lamivudine/efavirenz, and blood samples were collected before (baseline visit, defined as 0 months) and after 1, 3 and 6 months of treatment initiation.
Isolation ofplasma, leukocytes and platelets from blood samples
Blood was obtained from the patients after a 10-hour overnight fast and plasma, leukocytes and platelets were isolated as previously described (21, 23) . Briefly, 9 mL blood was obtained from each volunteer in 1 mL of an anticoagulant solution of sodium citrate/citrate acid. The sample was centrifuged at 194xg for 10 min at 25°C (151 centrifugation). Then the following three simultaneous procedures were carried out.
Isolation of plasma. The supernatant of the 1st centrifugation (plasma rich in platelets) was centrifuged at 1400 xg for 20 min at 25°C (2 nd centrifugation) in order to obtain plasma. Plasma was further centrifuged at 20,000xg for 1 h at 4°C, in order to remove the viral load, was aliquoted and stored at -80°C until the time of the LpPLA 2 assay analysis.
Isolation of human platelets (HPs). The pellet of the 2 nd centrifugation (platelets) was washed once with saline and after centrifugation at 1400 xg for 20 min at 25°C was re-suspended in 1 mL of a buffer containing 50 mM Tris-HCl (pH 7.4). Subsequently, platelets were sonicated on ice (4 x 15 s) and centrifuged at 500x g for 10 min at 4°C. Platelet homogenate after protein determination by Bradford method (24) was aliquoted and stored at -80°C.
Isolation of human leukocytes (HLs). In the pellet of the 1 51 centrifugation (leukocytes and erythrocytes) saline was added up to the volume of 10 mL and, after mixing by inversion, the solution was separated into two parts of 5 mL each. In each part the isolation of the leukocytes from the contaminating erythrocytes was achieved by erythrocyte sedimentation. An aliquot of 1.7 mL of dextran solution (3% dextran in NaCI 0.15 M) was added to each part and the mixtures were kept for 1 h at room temperature. The leukocyte-rich supernatants of the two aliquots were pooled and centrifuged at 500 xg for 10 min at 25°C. The supernatant was removed and contaminating erythrocytes of the sediment pellet were lysed with the addition of 5 mL of a lysis solution consisting of 155 mM NH 4Cl, 10 mM KHC0 3 , and 0.1 mM EDTA and then removed by centrifugation at 300 xg for 10 min at 25°C. The isolated leukocytes were re-suspended in 1 mL of a buffer containing 50 mM Tris-HCl (pH 7.4), sonicated on ice (4 x15 s) and centrifuged at 500 xg for 10 min at 4°C. Leukocyte homogenates after protein determination by Bradford method (24) were aliquoted and stored at -80°C.
PAF-CPT activity assays
The assay was performed on the homogenates of leukocytes and platelets as previously described (21, 23) . Briefly, the reaction was carried out at 37°C for 20 min in a final volume of200~L containing 100 mM Tris-HCl (pH 8.0),15 mM dithiothreitol (DTT), 0.5 mM EDTA, 20 mM MgCI 2 , lrng/ml, BSA, 100~M CDP-Choline, 100 M 1-0-alkyl-2-sn-acetyl-glycerol (AAG, added in the assay mixture in ethanol), and the sample (0.05 mg/mL final concentration of protein). The mixture ofTris, DTT, EDTA, MgCl 2 and BSA was incubated in 37°C for 5 min. Initially, the homogenate was added to the mixture. After 30 s, AAG was added and 30 s later the reaction was started by addition of CDP-Choline. The reaction was stopped by adding 0.5 mL of cold methanol (2% in acetic acid) after 20 min.
Lyso-PAF-AT activity assays
The assay was performed on the homogenates of leukocytes and platelets as previously described (21, 23) . Briefly, the reaction was carried out at 37°C for 30 min in a final volume of 200~L containing 50 mM Tris-HCl (pH 7.4), 0.25mg/mL BSA, 20~M Lyso-PAF and 200~M acetyl-CoA and the sample (0.125mg/mL final concentration of protein). The reaction was started by the addition of the homogenated sample and was stopped after 30 min by adding 0.5 mL of cold methanol (2% in acetic acid).
Determination ofproducedPAF and biosynthetic enzymes (PAF-CPT and Lyso-PAF-AT) activities
The extraction, purification and determination of the produced PAF in each assay were carried out as previously described (21, 23) . Briefly, PAF was extracted according to the Bligh-Dyer method (25) and was separated by thin-layer chromatography (TLC) on Silica Gel G coated plates with a development system consisting of chloroform:methanol:acetic acid: water (100:57:16:8, v/v/v/v). PAF band was scrapped off, extracted (25) and the amount of PAF was determined by the washed rabbit platelet aggregation assay (1).
All assays were performed in duplicate and specific activities of PAF-CPT and Lyso-PAF-AT were expressed as pmol of produced PAF/min/mg of sample protein present in each assay.
PAF-acetylhydrolase activity assays
PAF-AH in HLs and HPs as well as Lp-PLA 2 in plasma were determined by the trichloroacetic acid precipitation method using [3H] PAF as a substrate, as previously described (11) . Briefly, 0.05 mg of homogenates in the case of HLs, or 0.1 mg of homogenates in the case of HPs or 2 ul. of plasma were incubated with 4 nmol of [3H]-PAF (20 Bq per nmol) for 30 min at 37°C in a final volume of 200 ul, of 50 mM Tris/HCl buffer (pH 7.4). The reaction was terminated by the addition of cold trichloroacetic acid (10% final concentration). The samples were then placed in an ice bath for 30 min and subsequently centrifuged at l6,000xg for 5 min. The [3H]-acetate released into the aqueous phase was measured on a liquid scintillation counter. All assays were performed in duplicate. The enzyme activity of Lp-PLA 2 was expressed as pmol of PAF degraded per min per ul, of plasma and PAF-AH activity in HPs and HLs was expressed as pmol of PAF degraded per min per mg of sample protein.
Measurement of CD4 cell counts, viral load and biochemical markers in blood of HIV-infected patients and control subjects
CD4 cell counts were automatically calculated as previously described (21, 23) using Tetra One System on the EPICS XL flow cytometer, while viral load was determined using the Versant HIV-l RNA 3.0 assay (bDNA). The kit for this assay was purchased by Siemens Healthcare Diagnostics, Tarytown, NY, USA.
Serum total cholesterol (TC), HDL-Cholesterol, LDL-Cholesterol, triglycerides, oxaloacetic transaminase (AST), pyruvic transaminase (ALT), alkaline phosphatase (ALP), y-Glutamyltransferase (y-GT), creatinine and all the other biochemical parameters were measured as previously described (21, 23) using appropriate methods in a Siemens Dimension RxL automatic analyzer (Siemens Center, 60 MacPherson Road, Singapore 348615).
Statistical analysis
Normal distribution of variables was checked using Kolmogorov-Smirnov criterion. before further analysis. Normally distributed continuous variables are presented as mean values ± standard deviation.
Differences in enzyme specific activities and biochemical parameters were conducted using the repeated measures ANOVA criterion. Level of statistical significance was set at 0.05, whereas, due to multiple comparisons made by the repeated measures method, an emphasis was given for borderline significance that was set up to 0.05<p<0.10, only when the effect size together with the biochemical meaning were of importance.
Correlations were evaluated using the Pearson coefficient, while partial correlations with several cofounders were also conducted. Data were analyzed using a statistical software package, SPSS 18.0 (SPSS Inc., Chicago, Illinois, USA), and Microsoft Excel 2007 for Windows.
RESULTS

Anthropometric and biochemical characteristics of patients
Anthropometric and biochemical characteristics of patients before and after 1, 3 and 6 months of HAART (abacavir/ lamivudine / efavirenz) initiation are shown in Table I .
All patients had undetectable viral load «50 copies/mL) at 3 months, while their CD4 cell counts were significantly increased even from the 1st month of treatment. Regarding their lipid profile, triglycerides, total cholesterol, LDL cholesterol and HDL cholesterol were significantly increased. Glucose, ALP and rGT mean values were also increased, while bilirubin (total, direct and indirect) was decreased. Amylase was increased at 1 month of treatment compared to baseline, while it~as decreased at 6 months. AST, ALT, LDH, CPK, creatinine, urea nitrogen, K, Na, Ca(II) and P remained stable during the study period.
Effect of abacavir/lamivudine/efavirenz on PAFbasic biosynthetic enzymes, PAF-CPT and Lyso-PAF-AT, in blood cells (HLs, HPs) of HIV-infected patients
As far as PAF biosynthesis in blood cells ofthese patients is concerned, the activities of key PAFmetabolic enzymes during treatment are illustrated in Fig. 1 . During treatment, the mean values ofPAF-CPT specific activities, which is the enzyme in the de novo pathway, in both HLs and HPs were found relatively stable compared to those before HAART initiation (Fig. I, a, c) .
Regarding the remodeling pathway, the mean value of its main enzyme Lyso-PAF-AT specific activity of HLs was significantly increased, by approximately 68%, at the 3 rd month of treatment compared to baseline (p=0.043) (Fig. lb) . However, this increase did not persist at six months. Lyso-PAF-AT specific activity of HPs was also significantly increased (p=0.029), by approximately 70%, at the 3 rd month (Fig. Id) . Similarly to HLs, this increase did not persist at six months.
Effect of abacavir/lamivudine/efavirenz on both isoforms of PAF-catabolic enzyme, PAF-AH, in blood cells (HLs, HPs) and LpPLA 2 in plasma of HIV infectedpatients
Regarding PAF degradation, PAF-AH specific activity of HLs was borderline increased at the 3 rd month, by approximately 50%, compared to baseline (p=0.086) and significantly increased by approximately 47%, compared to the I" month of treatment (p=0.007). However, this increase did not persist at six months ( Fig. 2a) .
PAF-AH specific activities of HPs and plasma Lp-PLA z remained relatively stable during treatment compared to their activities before HAART initiation (Fig. 2b-c ). Correlations within PAF metabolic enzymes and with other biochemical parameters Pearson correlation coefficients within PAPmetabolic enzymes as well as between them and other baseline biochemical parameters are presented in Table II .
Concerning correlations within PAF-metabolic enzymes, PAF-CPT of HLs was found negatively correlated with Lyso-PAF-AT of HLs at baseline, a correlation that was borderline sustained at 1 (r=-0.55, p=0.09) and 3 months (r=-0.6l, p=0.05), and with Lyso-PAF-AT of HPs only at baseline. PAF-AH specific activity of HLs at baseline was found positively correlated with that ofHPs and also with LpPLA z . These correlations were not observed during treatment except a borderline one regarding PAF-AH of HPs (r=0.54, p=O.lO) at 3 months. PAF-AH activity of HPs was positively correlated at baseline with LpPLA z and Lyso-PAF-AT of HPs. These correlations were not observed during treatment.
LpPLA z specific activity was positively correlated at baseline with PAF-AH of both HPs and HLs and with viral load. These correlations were not observed during treatment. This enzyme was negatively correlated with BMI at baseline, a correlation that was reversed to positive at 6 months (r=0.6l, p = 0.05).
Concerning correlations between PAF-metabolic enzymes with biochemical parameters, PAF-CPT of HLs was positively correlated with total cholesterol and LDL cholesterol at baseline, a correlation that was sustained only at the 1st month (r=0.62, p=0.02) of treatment. Lyso-PAF-AT of HLs was negatively correlated with total cholesterol and LDL cholesterol only at baseline.
Regarding correlations ofPAF-metabolic enzymes with biochemical parameters of HIV infection, only Lyso-PAF-AT of HLs was found negatively correlated with CD4 cell counts at baseline. This correlation was diminished after adjusting for total cholesterol, LDL cholesterol, PAF-CPT of HLs and viral load while remained unaffected after adjusting for other cofounders. Correlations concerning Lyso-PAF-AT reappeared at 1 and 6 months of treatment.
Moreover, a borderline positive correlation between LpPLA 2 and viral load at baseline was observed, a correlation that was absent during treatment. However, the above correlation was diminished after adjusting for BMI, age, CD4 cell counts, PAF-CPT of HLs, Lyso-PAF-AT of HLs, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides as cofounder(s) (p > 0.10 in each case).
DISCUSSION
Limited and controversial data exist regarding interactions between HAART and inflammation, one of the main complications leading to increased cardiovascular risk and other HIV-related complications in HIV infected patients (18) (19) . Some studies have .shown that suppression of HIV with antiretroviral therapy actually improves some of the surrogate markers of cardiovascular disease (19) , while interruption of therapy may increase coronary risk (19) . However, other studies suggest that some antiretrovirals, such as abacavir, may promote systemic inflammation in some patients, as indicated by an increase in inflammatory markers (22, 26) .
In a SMART study, abacavir use has been associated with increased levels of the inflammatory biomarkers associated with CVD, IL-6 and hsCRP, and with vascular inflammation leading to instability of pre-existing atherosclerotic plaques (26) . On the contrary, other studies have reported no difference between patients receiving abacavir or tenofovircontaining regimens concerning inflammatory markers such as CRP, IL-6, IL-IO, and tumour necrosis factor alpha (TNFa) (27) .
However, no data exist about the effect of the first line abacavir/ lamivudine/efavirenz HAART regimen towards PAF and its metabolism, which is one of the inflammatory mediators implicated in increased cardiovascular risk and other HIV-related manifestations.
The present study reports for the first time that the first-line abacavir/ lamivudine/efavirenz HAART regimen enhances in vivo PAF-production, at least for the first months of treatment, by inducing PAF biosynthesis in blood cells, in naive, male, asymptomatic patients treated for a 6-month period. Induction ofPAF-biosynthesis occurred as a result of the increased levels ofLyso-PAF-AT activity in both HLs and HPs after 3 months of treatment, compared to baseline activity before HAART initiation. The activation of Lyso-PAF-AT in HLs seems to be more intense than that in HPs, since leukocytes contribute in a greater degree to PAF-biosynthesis than platelets; Lyso-PAF-AT activity in HPs was at least one order of magnitude lower than that of HLs at baseline (p<0.05) and during treatment.
Moreover, Lyso-PAF-AT activity of HLs was negatively correlated with CD4 cell counts at baseline, a correlation that reappeared after 1 and 6 months of treatment. This correlation was diminished in partial correlations after adjusting for viral load, implying that this correlation is somehow affected by viral load. This result is in accordance with previous reports showing that Tat protein induces the production of VEGF (14), a growth factor that seems to induce PAF biosynthesis by activating the remodeling pathway, especially Lyso-PAF-AT enzyme activity (28) . Therefore, since PAF downregulates CD4 proliferation (29) , it is possible that the negative correlation of Lyso-PAF-AT with CD4 cell counts at baseline reflects an implication of increased PAF levels in HIVinduced immunosuppression. This observation is in accordance with our previous data reporting a negative correlation between Lyso-PAF-AT of HLs and CD4 cell counts (9) . However, naive patients differed between our two studies in terms of duration of HIV infection and viral load levels (9) .
Since viral load decreased to undetectable levels after 3 months of abacavir/lamivudine/efavirenz treatment, the observed increase of Lyso-PAF-AT seems to be related mainly to this HAART regimen rather than viremia. Given that increase in Lyso-PAF-AT activity is implicated in pro-atherosclerotic inflammatory procedures (10), one may suggest that the induction of this inflammation-related enzyme activity during abacavir-containing HAART may be related to the observed excess of cardiovascular risk in such treatment.
However, Lyso-PAF-AT activity was reduced after 6 months of treatment, implying that, after this period, any risk related with increased PAFsynthesis ceases to exist. This finding is consistent with previous results suggesting that abacavirrelated cardiovascular risk is reduced after 6 months of treatment.
Concerning the de novo PAF-synthesis pathway, its main enzyme, PAF-CPT, of both HLs and HPs was found relatively stable during this treatment. Taking into account that PAF-CPT activity of HLs is increased in these patients at baseline compared to healthy subjects (9) , one may suggest that the abacavir/lamivudine/efavirenz regimen despite its effect in the remodeling pathway, and in contrast to other HAART regimens (20, 21) , does not further enhance or reduce the already increased de novo PAF-biosynthesis. Interestingly, at 1 and 3 months oftreatment, PAF-CPT activity ofboth HLs and HPs was negatively correlated with Lyso-PAF-AT ofHLs. However, the fact that PAF-CPT activity remains stable during HAART may further contribute to the increase ofPAF levels.
Regarding PAF degradation, abacavir/lamivudine/ efavirenz seems not to affect PAF-AH in platelets and plasma (LpPLA 2 ) . This is in accordance with the study of Klovidhunic et al. reporting that suppression of IlIV viremia by either a protease inhibitor or lamivudine was not accompanied by a lower level of LpPLA 2 activity (30) . In the present study we found that LpPL~activity was positively correlated with viral load at baseline, an observation that is consistent with our previous reports (9) . However, it should also be mentioned that the positive correlation of LpPLA 2 with viral load was diminished in partial correlations after adjusting for several cofounders such as LDL cholesterol which is known to be the main carrier of this enzyme in plasma.
In contrast to that in plasma (LpPL~) and platelets, the activity of PAF-AH in leukocytes was increased at the 3 rd month of treatment compared to baseline and 1 51 month. Similarly to Lyso-PAF-AT activity, this increase of PAF-AH in HLs was not sustained at six months. This suggests that the response of PAF-AH towards increased PAFsynthesis is more intense in HLs when compared to that in plasma, during 6 months of abacavir/ lamivudine/efavirenz treatment.
Considering all the above, our first reported findings of a transient increase of the inflammationrelated remodelling PAF-biosynthesis occurring in HIV-infected patients treated with abacavir/ lamivudine/efavirenz for a 6-month period, provide new perspectives and further support the observation that abacavir use is associated with pro-inflammatory processes implicated in atherosclerotic and cardiovascular complications t22, 26). On the other hand, other first-line HAART regimens containing Tenofovir-DF seem to reduce PAF biosynthesis leading to an opposite beneficial effect (20, 21) . The present and other similar studies provide a new insight into HIV therapeutics, giving the opportunity to reconsider the criteria for the choice of the most appropriate HAART regimen regarding inflammation.
However, further investigation is required to confirm these results and to unveil any possible clinical implications ofHAART-induced changes in PAF metabolism.
